Opendoor Technologies (NASDAQ: OPEN) shares fell 8.84% to $2.12 on October 16, 2026, on higher debt costs and fresh 52-week lows. Trading volume hit 64.6 million shares, about 53% above the three-month average. The stock had touched an all-time low of $1.93 on October 15 before a brief rally. It has fallen 80% since its 2020 IPO, as a sluggish housing market and rising interest rates weigh on the sector. In the second quarter, revenue dropped to $883 million from $1.6 billion a year earlier. Net loss widened to $162 million from $29 million. The company forecasts third-quarter sales growth of 20% year over year. Investors await early November earnings for guidance, liquidity, and margin trends.

Digbi Health brings precision biology care to all 50 states with 700+ clinicians and coaches through OpenLoop Health and MD Integrations. More than 300 employers and health plans now offer a unified platform for metabolic, inflammatory, and hormonal care, built on each member's gut microbiome, genetics, and glucose data, as a fully covered benefit. October 15, 2026 14:00 ET | Source: Digbi Health MOUNTAIN VIEW, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) - Digbi Health today extended its precision biology care to all 50 states through collaborations with OpenLoop Health and MD Integrations (MDI), giving members of more than 300 employers and health plans access to more than 700 physicians, nurse practitioners and coaches. Members can now receive GLP-1 medications and hormone replacement therapy (HRT) as part of the same food-first care plan that treats their metabolic, gastrointestinal, and inflammatory conditions. Food first, medication when needed Digbi brings obesity, metabolic, GI, and hormonal care together in one plan, built around the person's biology. Its proprietary AI platform reads each member's genetics, gut microbiome, blood biomarkers, glucose response, lifestyle, and medications, then personalizes care around food and lifestyle so that every meal becomes a chance to improve health. When a member needs a GLP-1 medication or hormone replacement therapy, a licensed clinician in Digbi's network can prescribe it as part of the same care plan, without a separate referral or app. The collaborations with OpenLoop and MDI make that step quick in all 50 states. A peer-reviewed actuarial claims analysis published in Healthcare, covering seven U.S. self-insured employers, found a $3,012 reduction in overall medical spend per member per year. From luxury to universal access "Precision biology changes lives only when it reaches people. For too long, it has been a luxury for those who could afford it. Our vision is to make it standard care, covered by health plans and employers. Our science identifies what drives each person's chronic illness. OpenLoop, MD Integrations, and Digbi's AI platform help us deliver the care that follows, in every state where our members live, to the standard patients and employers expect. Our clinical infrastructure now matches our vision and science." - Ranjan Sinha, Founder and Chief Executive Officer, Digbi Health The clinical backbone Digbi draws on OpenLoop's multi-state clinician network to give members access to licensed clinicians in the states where Digbi's programs are available, within a coordinated care experience. "Working with Digbi Health reflects a shared commitment to coordinated care. Access alone isn't enough; patients need the right clinician for the care they're seeking. OpenLoop's clinician network and operational infrastructure, combined with Digbi's personalized care programs, are designed to help reduce barriers to access." - Dr. Jon Lensing, CEO and Co-Founder, OpenLoop MDI's network of board-certified physicians spans all 50 states, the District of Columbia, Puerto Rico and Guam. It supports Digbi's synchronous and asynchronous care for GLP-1 medications and hormone replacement therapy, with built-in pharmacy and diagnostic workflows. The arrangement keeps clinical, pharmacy, and diagnostic standards consistent as Digbi's care volume grows. "Our relationship with Digbi Health rests on a shared commitment to clinical integrity and compliance. We provide compliant clinical infrastructure powered exclusively by physicians in all 50 states, because strong compliance systems help ensure patients receive appropriate care from clinicians licensed to provide it. By handling that framework behind the scenes, we let platforms like Digbi Health scale specialized care quickly and safely, without compromising on regulatory precision." - Dr. Marc Serota, Founder and CEO, MD Integrations About Digbi Health Digbi Health is the precision biology care company unifying metabolic and inflammatory care - including obesity, cardiometabolic, gastrointestinal, and inflammatory disorders. These illnesses share a root cause: a mismatch between an individual's biology and the one-size-fits-all lifestyle guidance they've been given. Digbi combines the gut microbiome, genetics, advanced blood biomarkers, and continuous digital health data to build a unique biological profile for each individual and identify what is driving their disease. AI then personalizes lifestyle treatment and, when needed, clinical treatment, delivered through the first precision-biology AI-orchestrated national telehealth platform. Through Digbi Labs, we invest in our vision of making chronic illness optional and advancing healthspan - partnering with leading universities, pharmaceutical companies, and scientific and clinical laboratories, running distributed human trials and publishing peer-reviewed research on genetics, the gut microbiome, and the use of AI to deliver care that is safe, cost-effective, and accessible. Digbi's healthcare cost reduction is documented in multiple peer-reviewed actuarial claims studies. Digbi is accessible to 30 million individuals through more than 300 employers and health plans. About MD Integrations MD Integrations is a clinical infrastructure company powering a physician-only network of board-certified MDs and DOs across all 50 US states, DC, Puerto Rico, and Guam. MD Integrations partners with more than 200 healthcare brands across specialties including weight management, longevity, women's health, and dermatology, giving founders and operators the clinical backbone to launch and scale compliant telehealth services without building physician networks or clinical infrastructure from scratch. Learn more at www.mdintegrations.com. About OpenLoop OpenLoop(R) provides white-label telehealth infrastructure and operational support that helps organizations launch and scale virtual care, including clinician staffing and credentialing, technology, and pharmacy and lab logistics. Clinical care is delivered by licensed clinicians through the applicable licensed clinical entity. OpenLoop supports more than 400 organizations and has been recognized on TIME's Top HealthTech Companies (2025 and 2026). To learn more, visit openloophealth.com. Media Contact Aniiket Sengar VP Marketing Operations, Digbi Health [email protected] OpenLoop is a registered trademark of OpenLoop Health, Inc.

Astrin, OpenLoop expand breast cancer blood testing. The partners aim to expand access to Certitude, a blood test intended to supplement a mammography for women with elevated cancer risk, across 48 states. By Nathan Eddy | October 9, 2026 | 1:30 PM Eligible women in 48 states can now access a supplemental breast cancer blood test through telehealth under a distribution partnership between Astrin Biosciences and OpenLoop Health. The companies announced the rollout of Astrin's Certitude test, saying the expansion could reach approximately 75 million women. The test is designed to identify protein patterns associated with breast cancer, including disease as early as Stage 0. OpenLoop supplies the clinical infrastructure, including physician ordering, home or local blood collection, and guidance after results are returned. Patients submit their information online for a licensed provider to review and determine eligibility. The offering targets women with dense breast tissue or elevated breast cancer risk who may need additional screening. Certitude is intended to supplement mammography, rather than replace it. Astrin's platform combines mass spectrometry, which measures proteins in a blood sample, with machine learning to identify patterns associated with cancer. The approach examines protein signals rather than relying on imaging or detecting tumor DNA circulating in the blood. The company's patient website lists eligibility beginning at age 40 and says the test has not been evaluated during pregnancy, with people with autoimmune disorders or with those with a personal history of cancer other than nonmelanoma skin cancer. Certitude is a laboratory-developed test and has not been cleared or approved by the FDA. The company lists an introductory self-pay price of $525 for requests submitted through Dec. 31, 2026, and says insurance coverage is not currently available. Women in New York and Hawaii can check eligibility and join a waitlist; however, the test is not yet available in those states. THE LARGER TREND OpenLoop has been expanding its services through its virtual care infrastructure. In June, it partnered with RxHealing and Tenovi on a pharmacy-driven remote patient monitoring program, providing clinical oversight, compliance and billing support while pharmacies identified eligible patients and Tenovi supplied connected devices. The company previously raised $15 million in 2023 and announced a nationwide payer network and revenue cycle management service for digital health companies. The Certitude rollout also follows efforts to connect women's cancer screening with care outside traditional clinical settings. In July, Teal Health and UC Davis Health launched an at-home cervical screening pilot for women due or overdue for screening. That study is evaluating whether home sample collection can improve participation and integrate with health system workflows. HIMSS is hosting the one-day AI Executive Leadership Summit in San Diego on Oct. 21, 2026, followed by its AI in Healthcare Forum Oct. 22-23. Register separately for the two events here and here. WATCH NOW: Tech meets nurses' needs and improves retention